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Sudden Cardiac Death - A Review
SIU-HONG WAN
From Department of Medicine, Tuen Mun Hospital, Tuen Mun, Hong Kong

WAN: Sudden Cardiac Death - A Review. Each year, more than 300,000 people in the United States suffer from
sudden cardiac death. It may be due to a combination of both structural and functional elements whereby a structural
substrate is destabilized by functional elements to trigger the life-threatening arrhythmia. Common underlying
aetiologies for sudden cardiac death include coronary artery diseases, myocardial diseases like hypertrophic and
dilated cardiomyopathies, electrophysiological disorders like congenital and acquired long-QT syndrome, WolffParkinson-White and Brugada syndrome. The management strategies, risk stratification, primary and secondary
prevention of sudden cardiac death are reviewed. However, not only patients with high risk estimated by current
predictors are prone to sudden cardiac death, most such deaths occur in the general population currently considered
not to be at high risk. Thus, in order to make a significant impact on the public health, we should focus on developing
effective risk markers and devising broader strategies to prevent sudden cardiac death in the general population.
(J HK Coll Cardiol 1999;7:18-31)

1. Introduction
Sudden cardiac death is defined as unexpected
death due to cardiac causes that occurs within one hour
of acute symptoms. There is the sudden, abrupt loss of
heart function (i.e. cardiac arrest) in a person who may
or may not have diagnosed heart disease. Cardiac
arrhythmias (e.g. ventricular fibrillation), sudden pump
failure (e.g. acute myocardial infarction), acute
circulatory obstruction (e.g. pulmonary embolism) and
cardiac rupture are some of the commonest causes.
Sudden cardiac death due to ventricular arrhythmias is
a significant cause of mortality in patients with coronary
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artery and structural heart diseases.
Each year, more than 300,000 people in the
United States and 100,000 people in the United
Kingdom suffer from sudden cardiac death. Sudden
death can strike people of any age and sex but it typically
occurs in males with an average age of 65 years and
more than 80% have coronary heart diseases. In around
20% of cases, sudden death is the first manifestation of
disease.
In the past 30 years, advances in the ability to
identify and modify risk factors associated with sudden
cardiac death, prompt resuscitation and defibrillation,
appropriate surgical and medical treatments with drugs
like aspirin, beta blockers, antiarrhythmics and
thrombolytics, and more recently, implantation of
antiarrhythmia devices results in the reduction of ageadjusted sudden cardiac death mortality rates. However,
sudden cardiac death remains a common clinical
problem that all physicians are likely to encounter.
In the present essay, the evaluation, management,
primary and secondary prevention of sudden cardiac
death are reviewed.
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2. Pathophysiology and Aetiology

and proarrhythmia due to various drugs.
The observation of a circadian variability in the
incidence of sudden cardiac death with a prominent peak
in the early morning hours provides evidence that
transient disturbances in the autonomic tone can
predispose the heart to increased electrical vulnerability.
Analysis of heart rate variability (HRV) provides further
evidence of reduced vagal and elevated sympathetic tone
during the morning hours particularly in patients with
compromised left ventricular function. Diurnal
variations in ventricular repolarization as indicated by
QT interval changes in the surface ECG also support
the concept of triggering factors in the genesis of sudden
cardiac death2,3.
Most episodes of sudden cardiac death are
thought to be due to VF. VF may be "primary" when it
is not resulting from the consequence of haemodynamic
deterioration or "secondary" when it is precipitated by
such event. Occasionally, VF may be due to
degeneration from a sustained VT.
In some cases of sudden cardiac death,
bradycardia, asystole or electromechanical dissociation
may be the underlying rhythm. This can be a primary
event seen commonly in patients with end stage heart
failure or terminal illness or a secondary event seen in
patients as a result of delay rescue from ventricular
fibrillation.

A proposed pathophysiological model for sudden
cardiac death combines both a structural and functional
elements whereby a structural substrate is destabilized
by functional elements to trigger the life-threatening
arrhythmia. This interaction may convert premature
ventricular complexes into triggering events for
ventricular tachycardia (VT) and ventricular fibrillation
(VF) resulting in circulatory collapse, cerebral
hypoperfusion, loss of consciousness, respiratory arrest
and then death. Figure 1 showed the various contributing
factors for sudden cardiac death1.
The most common triggering factors are acute
myocardial infarction (AMI) or coronary ischaemia
(chronic or acute spasm), previous myocardial infarction
(MI) with scarring and aneurysm formation. Other
structural risk factors includes hypertrophic and dilated
cardiomyopathy, arrhythmogenic right ventricular
dysplasia, myocarditis, infiltrative myocardial diseases,
Wolff-Parkinson-White syndrome with fast conducting
antegrade accessory pathways, valvular heart disease
and mitral valve prolapse.
Electrical abnormalities which predispose to
sudden cardiac death include congenital and acquired
long QT syndrome, the Brugada syndrome, systemic
factors (hypoxia, acidosis and electrolyte disturbance)
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Figure 1. Structure, function and the pathogenesis of sudden cardiac death
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2.1

Coronary Artery Diseases

In the United States and Europe, coronary artery
disease is the most common diagnosis in sudden cardiac
death. Autopsy and clinical studies have shown that 80%
of patients with sudden cardiac death have
atherosclerotic coronary artery disease and coronary
thrombi may be detected in up to 50% of sudden death
victims. But only about 25% of patients resuscitated
from an out-of-hospital cardiac arrest will develop new
Q wave infarction with another 25% of patients showing
enzymatic evidence of necrosis.
Several mechanisms have been proposed as
causes of potential fatal arrhythmias. In a patient with
acute myocardial infarction, the sudden occlusion of a
coronary vessel due to rupture of artherosclerotic plaque
will result in acute ischaemia and ventricular fibrillation.
Patients with known coronary artery disease or history
of MI with scarring of the related myocardium will have
an anatomical substrate consisting of intercalating
fibrosis and normal myocytes. This will produce areas
of slow conduction and block of normal electrical
propagation resulting in re-entry circuit formation and
ventricular tachyarrhythmias. In other cases, a
combination of ischaemia, reperfusion, electrolyte
disturbance, autonomic dysfunction or drug toxicity
contribute to the generation of ventricular
tachyarrhythmias. Arrhythmogenic mechanisms in such
cases include re-entry, enhanced automaticity and early
afterdepolarizations.
Other causes of cardiac death related to the
coronary arteries include coronary artery spasm (e.g.
substance abuse with cocaine), anomalous coronary
anatomy (e.g. congenital anomalous origin or course
of coronary artery), embolism, trauma or arteritis.

2.2

Myocardial Diseases

2.2.1 Hypertrophic Cardiomyopathy
Myocardial hypertrophy has been defined as a
risk factor of sudden cardiac death. The hypertrophy
can be primary like in cases of hypertrophic
cardiomyopathy or secondary as in cases of
hypertension. In hypertrophic cardiomyopathy
(HOCM), sudden death tends to occur in young adults
especially during vigorous exercise. It accounts for
around 5-10% of sudden cardiac deaths. Risk factors
include significant symptoms of heart failure, family
history of sudden death and nonsustained ventricular
tachycardia. Unfortunately, the underlying
electrophysiological abnormality from individual
mutations are not understood though polymorphic
ventricular tachycardia or ventricular fibrillation is
20

thought to be the initial event at the time of cardiac
arrest4. In some cases, AV block with asystole or rapid
supraventricular tachycardia is the initial event.
2.2.2 Dilated Cardiomyopathy
Non-ischaemic dilated cardiomyopathy
contributed to about 10% of resuscitated cardiac arrest
victims and sudden death accounts for about 50% of all
deaths in this group of patients. Sudden death usually
occurs late in the course of disease compared with
patients suffering from hypertrophic cardiomyopathy.
In this group of patients, monomorphic or polymorphic
ventricular tachycardias are usually implicated as the
cause of sudden cardiac death. Amonomorphic
ventricular tachycardia involving marco-reentry using
the His-Purkinje system has been reported in some
patients with dilated cardiomyopathy.
Histology of the myocardium indicates myocyte
death and replacement by fibrous tissue as well as
hypertrophy of remaining myocytes. Systemic factors
such as haemodynamic dysfunction in congestive heart
failure, hypoxemia, acidosis, electrolyte disturbances
like hypokalaemia and neurophysiological interactions
contribute to the cardiac electrical instability. In
patients with advance heart failure, bradyarrhythmias
may account for more than 50% of sudden cardiac
deaths.
2.2.3 Miscellaneous
Left or right ventricular dysfunction due to
various heart diseases like rheumatic heart diseases,
congenital heart disease, arrhythmogenic right
ventricular dysplasia (ARVD), infiltrative and
inflammatory myopathic diseases (e.g. myocarditis) can
predispose to sudden cardiac death.
In ARVD, there is a regional myopathy of
predominantly the right ventricle with the affected
myocardium infiltrated with fatty vacuolization and
fibrosis. Patients with ARVD are subjected to recurrent
episodes of sustained monomorphic ventricular
tachycardia or even polymorphic ventricular tachycardia
with left bundle branch block pattern and multiple QRS
morphologies.
Patients with corrected congenital heart diseases
like Fallot’s tetralogy may develop arrhythmias
originating from the right ventriculotomy or septal
repair sites.

2.3

Electrophysiological Disorders

Electrophysiological disorders can result in
sudden cardiac death. These include congenital and
acquired long-QT syndrome, Brugada Syndrome and
Wolff-Parkinson-White Syndrome (WPW).
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2.3.1 Congenital long-QT syndrome
In congenital long-QT syndrome (LQTS), a
family history of sudden cardiac death is often present
although sporadic cases had been reported. Mortality
rates in untreated symptomatic patients with congenital
LQTS are 26%, 35% and 53% at 3, 5 and 15 years
respectively 5 . Sudden cardiac death is usually
precipitated by adrenergic triggers like stress or
exercise.
Molecular biology underlying the syndrome
involves link to chromosome 3 (SCN5A sodium channel
gene), 4, 7 (HERG potassium channel gene) and 11
(KVLQT1 gene) for LQT3, LQT4, LQT2 and LQT1
respectively. Slowly (IKs) or rapidly (IKr) activating
component of the delayed rectifier or the cardiac sodium
channel (INa) are involved6.
The QT intervals in patients with congenital
LQTS and their family (gene carriers) are usually
prolonged but can be normal in about 5 to 10% cases.
Another important feature is that the QTc value in a
patient with LQTS may be variable and may be normal
at times. Therefore, the diagnosis include ECG findings
(prolonged QTc, torsade de pointes, T wave alternans),
clinical history (syncope, congenital deafness) and
family history of unexplained sudden death. With the
recent advances in molecular genetics, it is hoped that
the condition can be diagnosed accurately prior to the
occurrence of any life-threatening arrhythmias5.

electrophysiological mechanism is due to early
afterdepolarization (EAD) resulting in torsades de
pointes (TdP) type of polymorphic ventricular
tachycardia. The initiation of TdP can be pause
dependent, associated with a long-short sequence, shortlong sequence or cascade phenomenon. Premature
depolarization generates a post-extrasystolic pause, the
sinus complex that followed shows marked TU changes
and a subsequent ventricular extrasystole originates.
This generates a new pause, followed by more bizarre
TU changes from which progressive longer and faster
runs of polymorphic ventricular tachycardia originate5.

2.3.2 Acquired long-QT syndrome
In acquired long-QT syndrome, prolong QT
interval is commonly associated with electrolyte
disturbances or various drugs as shown on Table 1. The

2.3.5 Brugada Syndrome
Recently, Brugada reported data on a group of
patients with electrocardiographic (ECG) findings of
right bundle branch block pattern and persistent ST
segment elevation in lead V1 to V3 and sudden cardiac
death. Structural heart disease or coronary artery disease
had been excluded in this group of patients. They have
a mean age of 40 with a male to female ratio of 8:1.
The prodromal symptoms of nocturnal sudden death
are seizures or syncope. In the recent report by Brugada
in February, 1998, during a mean follow up of 34 months
in 63 patients, an arrhythmic event occurred in 14
symptomatic patients (34%) and 6 asymptomatic
patients (27%) suggesting that these patients have a
relatively high risk of sudden death7.
The high take-off ST segment elevation is either
the coved or saddle-back type. There are several
proposed underlying mechanism for the ST segment
elevation in Brugada syndrome, including
intraventricular conduction disturbance, early
ventricular repolarization, local ventricular
depolarization and sympathetic imbalance8,9. Mutations
in the cardiac sodium channel gene, SCN5A, causing
either an acceleration of the recovery of the sodium

Table 1. Causes of acquired long-QT syndrome
Hypokalaemia
Hypomagnesaemia
Hypocalcaemia
Quinidine (other Class Ia antiarrhythmic drugs)
Amiodarone and sotalol (other Class III antiarrhythmic
drugs)
Amitriptyline (other tricyclic antidepressants)
Chlorpromazine (other phenothiazine drugs)
Terfenadine and astemizole
Erythromycin
Cisapride
Pentamidine
Organophosphate insecticides
Cocaine
Probucol
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2.3.3 Bradyarrhythmias
Bradyarrhythmias can also cause sudden cardiac
death. For patients with congenital heart block, the
escape pacemaker may deteriorate in time with
ventricular arrhythmias appearing as the patient’s
bradycardia becomes more and more inappropriate.
2.3.4 Wolff-Parkinson-White Syndrome
Supraventricular ventricular tachycardia with
very rapid ventricular rates can cause haemodynamic
collapse. Atrial fibrillation in patient with WolffParkinson-White Syndrome (WPW) may result in very
rapid conduction via the accessory pathway down to
the ventricle, thus producing ventricular tachycardia and
fibrillation.
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channel (missense mutation) or nonfunctional sodium
channels (insertion and deletion mutations) had been
reported recently in early 199810. Diagnosis involves
programmed ventricular stimulation to induce
ventricular tachyarrhythmias and the use of drugs like
ajmaline, flecainade and procainamide to augment the
ST segment elevation.
The author has recently encountered a 28 years
old gentleman who might be the first reported case of
Brugada syndrome in Hong Kong. He had no history of
drug abuse but there was family history of syncope
attacks. He was admitted to Tuen Mun Hospital because
of syncope and convulsion. Cardiac monitoring during
the convulsive attack showed polymorphic VT (with
absent central pulses) which reverted to sinus rhythm
spontaneously. The baseline ECG showed the typical
high take-off ST segment elevation in V2. Further
investigations including serum electrolytes, cardiac
enzyme, toxicology screening, echocardiogram,
angiography, left ventriculography and magnetic
resonance imaging of the heart (to rule out ARVD) were
all normal. Programmed ventricular stimulation showed
inducible ventricular fibrillation with 2 or 3 extrastimuli
in the right ventricular apex or outflow tract. After
intravenous infusion of procainamide, the ST segment
elevation was augmented in V2 and aVL as shown in
Figure 2.
Some patients with structurally normal hearts,
who survive sudden cardiac death, exhibit none of the
above discussed characteristics and the precise
underlying causes cannot be defined. Their

electrophysiological studies and Holter monitoring
results are often normal.

3. Management Strategies
The management strategies of sudden cardiac
death involves immediate resuscitation with
defibrillation, identification and prompt correction of
reversible underlying precipitating factors, risk
stratification, drug therapy, device implantation, follow
up and prevention of recurrence. Under this section,
management strategies will be discussed with respect
to primary and secondary prevention. Risk stratification
is discussed under Section 4.

3.1

Immediate Response and Automated
External Defibrillators (AEDs)

With the development of community based
cardiopulmonary resuscitation (CPR) programmes,
more and more people are trained for immediate CPR.
Figures from the United States have shown that
approximately 40-50% of patients can be stabilized in
the field and transferred to the emergency department
and 24% successfully discharged. The timing from
cardiac arrest to the initiation of CPR and prompt
defibrillation is crucial for the survival of the sudden
cardiac arrest victim. The chances of survival drop by
10% for every 1 minute delay, thus, after around 10-12
minutes, the survival rate is less than 20%. A half-year
study carried out by the Hong Kong Ambulance

Baseline

After procainamide

Figure 2. Augmentation of ST segment elevation after procainamide in the 28 years old gentleman
22
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Services showed that only 8.9% (66 out of 744 arrests)
of cardiac arrest victims received bystander CPR and
the arrest to first shock interval was a significant factor
related to survival. However, only 1.6% of these victims
were discharged alive which was below the world
standard. Therefore, the author concluded that in order
to improve survival rates of out-of-hospital arrests,
arrest to shock interval must be reduced and the
frequency of bystander CPR increased11.
The American Heart Association has supported
the concept of the need of the “chain of survival" to
rescue the person who suffers cardiac arrest in the
community. The chain consists of: 1). Early Access 2).
Early CPR 3). Early Defibrillation 4). Early Advanced
Care (Figure 3).12

Figure 3. The Chain of Survival12

The development of the Automated External
Defibrillator (AED) in the community to provide early
and prompt defibrillation improves the chance of
survival of cardiac arrest patients. The device is
designed to recognize many variations of ventricular
arrhythmias while at the same time ensuring that it does
not inappropriately detect other rhythms. Most AED
manufacturers have exceeded the AHA requirement for
the specificity and sensitivity.
In Hong Kong, most ambulances and all St.
John’s ambulances have installed the AED. This device
can automatically detect and analyze the cardiac rhythm,
deliver the external defibrillation using biphasic energy
shock and give voice alert and command to the medical
personnel.
With the further development of the AED,
personnel training and the collaboration of different
parties e.g. Fire Services Department, Heath Services
Department and private corporations, it is hope that the
device can be installed in all international airlines, large
corporations, shopping malls and even in the home of
patients with high risk of sudden cardiac death. Much

J HK Coll Cardiol, Vol 7

coordination and communication work is still awaited
to achieve this goal.

3.2

Acute Management

Upon arrival at the Accident and Emergency
Department, advanced cardiac life support should be
instituted immediately. This includes securing the
airway, intubation with oxygenation, defibrillation,
CPR, intravenous access, cardiac drugs (e.g. adrenaline,
lignocaine, procainamide, bretylium, etc.), and
correction of electrolyte and acid-base disturbance. In
cardiac arrest patients with asystole, bradycardia or heart
block, an external or transvenous cardiac pacemaker
can be placed. In cases of electromechanical
dissociation, underlying causes like hypovolemia,
tamponade, hypoxemia, tension pneumothorax,
acidosis, hyperkalaemia and massive pulmonary
embolism should be treated.
Magnesium, isoprenaline and overdrive pacing
are particularly useful in cases of TdP type of
polymorphic ventricular tachycardia occurring in
patients with acquired long-QT syndrome.
The management of AMI and acute coronary
syndrome involve standard treatments like aspirin,
thrombolytics, angioplasty (PTCA), heparin, beta
blockers, angiotensin converting enzyme inhibitors
(ACEI) and antiarrhythmics. For AMI, early ventricular
fibrillation or ventricular tachycardia within 48 hours
of the initial event do not portend a poor long term
prognosis, and the management of these patients is
therefore that of the acute infarction itself.
Other investigations include electrocardiography
(to document AMI, acute ischaemia, WPW syndrome,
long-QT syndrome, Brugada syndrome),
echocardiography (to document regional myocardial
function, valvular and anatomical abnormalities,
pericardial effusions), cardiac catheterization (will be
discuss later under Section 3.5), myocardial biopsy (for
myocarditis) and magnetic resonance imaging (for
ARVD).

3.3

Antiarrhythmic Drug Therapy

Previously, class I antiarrhythmic agents, beta
blockers and class III antiarrhythmic agents were used
to treat complex ventricular arrhythmias hoping to
prevent sudden cardiac death13.
Concerning the use of antiarrhythmics for
primary prevention of sudden cardiac death, there were
several randomised studies. Based on the publication
of the Cardiac Arrhythmia Suppression Trial (CAST)
and CAST II14,15 showing excessive mortality with the
use of class IC agents (flecainide, encainide and
moricizine) in post infarction patient, these agents are
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not recommended. Results from the Electrophysiologic
Study Versus Electrocariographic Monitoring
(ESVEM) trial 16 , the Cardiac Arrest in Seattle:
Conventional versus Amiodarone Drug Evaluation
(CASCADE) 17 and several smaller studies (Basel
Antiarrhythmic Study & Infarct Survival BASIS18 and
Polish Amiodarone Trial PAT 19 ) showed that
amiodarone and sotalol are more effective than other
antiarrhythmic agents in the prevention of recurrent
sustained ventricular tachycardia and the sympathetic
inhibition component of these drugs do contribute to
mortality reduction.
However, the development of a so-called pure
class III antiarrhythmic agents had been hampered by
the Survival With Oral d-Sotalol (SWORD) Trial 20
which showed increased mortality among patients
assigned to d-sotalol. This trial intended to show that a
pure potassium-channel blocking action could reduce
all-cause mortality in patients with previous myocardial
infarction and left ventricular dysfunction but was
prematurely terminated when an interim analysis
showed the increased mortality.
Beta-blockers are associated with highly
significant reductions in risk of death in post-infarction
patients (56 trials, 53,521 patients: OR 0.81; 95% CI
0.75 to 0.87, P < 0.00001). The survival benefit appears
to be mediated by both a reduction in arrhythmia-related
death (25-30%) and recurrent infarction. Recent interest
in use of carvedilol, a beta blocker with antioxidant and
a-adrenergic blocking activity in congestive heart failure
requires further exploration. Carvedilol has been shown
to decrease incidence of resuscitated VT or VF,
unexplained syncope and sudden death in patients with
congestive heart failure from 25% to 9%21.
The European Myocardial Infarction Amiodarone
Trial (EMIAT) 22 had shown that amiodarone has no
impact on overall survival (all cause mortality 11.3%
in the amiodarone group versus 12.1% in the placebo
group) despite some improvement in sudden death
survival in patients with depressed left ventricular
function following MI (arrhythmic death 5.6% in
amiodarone group and 8.2% in the placebo group). The
Canadian Amiodarone Myocardial Infarction
Arrhythmia Trial (CAMIAT)23 recruited survivors of
recent MI (within the last 6 to 45 days), and randomized
them to either amiodarone or placebo. The protocol
required patients to have complex ventricular ectopy,
defined as more than or equal to 10 ventricular
premature depolarizations per hour or nonsustained
ventricular tachycardia (NSVT). There was a
statistically significant reduction in the primary endpoint
of VF or arrhythmic death in patients assigned to the
amiodarone group. However, there was a non-statistical
24

trend toward decreased all-cause mortality in patients
randomly assigned to amiodarone. Using efficacy
analysis, there was a 21.2% reduction in total mortality
with amiodarone (37% versus 50%, P=0.136). Using
intention-to-treat analysis, there was a statistically nonsignificant 18.3% reduction in all-cause mortality (57%
versus 68%, P>0.15).
For primary prevention of sudden cardiac death
in patients with congestive heart failure, the Grupo de
Estudio de la Sobrevida en la Insuficiencia Cardiaca en
Argentina (GESICA)24 study showed that amiodarone
treated patients with advanced stable heart failure had
lower mortality than the control group (33.5% versus
41.4% P=0.024). There were also reductions in sudden
death and death from progressive heart failure. The
Veterans Affairs Congestive Heart Failure: Survival
Trial of Antiarrhythmic Therapy (CHF STAT)25 had
shown that amiodarone treated patients with ejection
fraction ≤40% and asymptomatic but frequent and
complex ventricular arrhythmias had a trend towards
reduction in hospitalizations and cardiac death
combined, which is significant in patients with nonischaemic aetiology.
Overall data from the amiodarone trials on high
risk patients (post-infarction, congestive heart failure
or survivors of cardiac arrest) suggest that this agent is
effective in reducing the risk of death (14 trials, 5713
patients: OR 0.83; 95% CI 0.72 to 0.95, P = 0.01).
In summary, for the primary prevention of sudden
cardiac death, beta blockers are shown to be particularly
effective in post infarction patients, sotalol and
amiodarone are effective for high risk patients and
carvedilol is promising in patients with congestive heart
failure. For the routine prophylactic use of amiodarone
and sotalol in post MI patients, evidences suggested
that they only have a limited role at the present
moment 26. Discontinuation of these antiarrhythmic
drugs is high due to intolerance or adverse effects.
Nevertheless, as the group of patients with increased
risk of recurrent ventricular tachyarrhythmias were
heterogeneous, further randomized trials are needed to
clarify the present controversies in choosing the best
antiarrhythmic drug in particular subgroups of patients
in different clinical settings.
Holter or electrophysiological study guided
antiarrhythmic therapy have been advocated.
Suppression of arrhythmias guided by these methods
was associated with a good clinical outcome. The
ESVEM study showed that while Holter monitoring
led to predictions of antiarrhythmic drug efficacy
more often than the electrophysiological study, there
was no statistical significant difference in the clinical
success of drug therapy as selected by the two
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methods16.
In secondary prevention of sudden cardiac death
(i.e. in survivors of cardiac arrest), several recently
published randomized studies had shown that the
implantable cardioverter defibrillator (ICD) is the
treatment of choice when transient or reversible causes
are excluded (discussed under Section 3.7).
Nevertheless, antiarrhythmic drugs remain useful in
patients not suitable or not indicated for ICD
implantation, as well as for acute control of arrhythmias
and as adjunctive treatment to ICD (decreasing the
frequency of shocks, slowing ventricular tachycardia
rate to within the antitachycardia pacing window,
treating atrial arrhythmias, etc.)27

3.4

Radiofrequency Catheter Ablation

In recent years, the development of catheter based
radiofrequency ablation technique has allowed a safe
and effective treatment of cardiac arrhythmias. The
success rate is greater than 90% for supraventricular
ventricular tachycardias involving accessory pathways
or nodal re-entry.
In patients with WPW syndrome and atrial
fibrillation, ablation of the atrioventricular accessory
pathway will be curative and prevent the recurrence of
rapid ventricular tachycardia (VT) and fibrillation.
This ablation technique is also very effective in
treating VTs in structurally normal hearts. The two
major group of VTs arise from the right ventricular
outflow tract (VT with left bundle branch block pattern
and right axis deviation) and the posterior fascicle of
the left ventricle (verapamil-sensitive fascicular VT with
right bundle branch block pattern and left axis deviation)
respectively. Bundle branch reentrant VT is also
amenable to catheter ablation.
At present, radiofrequency catheter ablation of
post-MI or ischaemic VT has only a limited role and is
time consuming. The clinical ventricular tachycardia
must be reliably reproducible in the electrophysiological
laboratory, well tolerated clinically and sustained
enough to be mappable. Due to the intrinsic limitation
of radiofrequency current, the reentry pathway, if based
on circus movement, must be relatively subendocardial.
However, de Bakker et al found that the earliest and
latest endocardial sites of activation were connected
through scar tissue by bands of surviving myocardial
fibers that could run subendocardially, intramurally and
even epicardially28. The patient should have limited
number of morphologically distinct ventricular
tachycardia patterns. Ablation will be difficult and the
end point uncertain if nonclinical tachycardia is induced
during electrophysiological study.
The method of ablating the tachycardia rests on
J HK Coll Cardiol, Vol 7

endocardial catheter electrode mapping of the earliest
site of activation, pace mapping, concealed entrainment
and identification of mid-diastolic potentials. The
definition of the endpoint of ablation has not been fully
resolved. Where ventricular tachycardia was difficult
to induce and to reproduce, the predictive value of
permanent success may be diminished.
Finally, remodelling of the myocardium is a
progressive process and previously stable substrates can
become arrhythmogenic with time. As a result, the major
use of catheter ablation in cardiac arrest or ischaemic
heart patients is as an adjunct treatment to lessen the
frequency of arrhythmias after ICD implantation and
thus decrease the number of shocks.
In future, with the development of new ablation
and mapping techniques (e.g. 3D mapping with
CARTO-system29, microwave or transmural ablation,
etc.), it is hoped that the clinical application of
radiofrequency ablation in ischaemic VT will be greater.

3.5

Angioplasty and Coronary Bypass Surgery

Cardiac catheterization provides the most
complete assessment of the structure, function and
coronary arteries of the heart. It should be performed in
virtually all survivors of cardiac arrest. Angioplasty
should be performed in patients with evidence of
ischaemia and significant critical stenosis. Studies have
shown that an open infarct-related artery may prevent
the development of the abnormal electrophysiological
reentrant circuit by allowing a more homogenous area
of infarcted tissue to form. However, its exact role in
the prevention of sudden cardiac death awaits further
prospective controlled trials.
In patients with ischaemic heart disease and
angina, surgical coronary revascularization decrease
sudden death rates, with greatest benefits observed in
patients with depressed left ventricular function and
multiple vessel disease. Among cardiac arrest survivors,
revascularization is indicated in patients with evidence
of ischaemia. Although it is uncertain whether
revascularization will alter the frequency of spontaneous
episodes of arrhythmia, it may improve the patient’s
ability to tolerate an episode of VT and may also inhibit
the development of new arrhythmias.

3.6

Other Surgical Therapies

Other surgical therapies play important roles in
the management of both cardiac arrest survivors and
patients at risk of sudden cardiac death.
Direct surgical approach to eliminate or ablate
the VT focus arising from the scarred or aneurysmal
tissue have been developed. These techniques employed
epicardial and/or endocardial mapping and programmed
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ventricular stimulation to locate the presumed site of
origin of the VTs followed by surgical resection or
ablation (e.g. using cryothermia or laser). The major
drawback of arrhythmia surgery is the operative
morbidity and mortality (5% to >20%), thus this option
is limited for use in selected patients and experienced
centers.
Surgical therapy can also be effective in certain
group of patients with risk of sudden cardiac death.
Examples include left cervicothoracic sympathectomy
in patients with congenital long-QT syndrome who
failed medical therapy and septal myotomy in patients
with hypertrophic obstructive cardiomyopathy.
Orthotopic heart transplantation has emerged as
an acceptable therapeutic alternative for selected
patients with end stage heart failure and resistant
ventricular arrhythmias.

3.7

Implantable Cardioverter Defibrillator
(ICD)

The concept of an ICD was developed by Michel
Mirowski in 1966-7. Since the first human implant of
ICD in 1980, significant interest and enthusiasm has
developed all over the world for the use of ICDs for
patients with life-threatening ventricular
tachyarrhythmias. More than 10,000 ICDs have
subsequently been implanted worldwide.
As rapid technical advancement continues, the
ICD has evolved from a short-lived, large-size, nonprogrammable device requiring a thoracotomy for lead
insertion into a multiprogrammable, small-size,
antiarrhythmia device inserted almost exclusively
without thoracotomy, now capable of treating
bradycardia, VT and VF. These devices are capable of
correctly sensing the arrhythmia (facilitate by using
rate, onset, stability criteria and atrial sensing),
delivering antitachycardia pacing (ATP), low energy
shock, achieving a lower defibrillation threshold
(by using biphasic shock), storing intracardiac
electrocardiograms, extensive diagnostics, backup
pacing and transvenous implantation.
Recently, defibrillators incorporating an atrial
lead have become available, such device not only
provide dual-chamber pacing but also use the pattern
of sensed atrial depolarization to distinguish
supraventricular from ventricular arrhythmias. Over the
years, ICDs have achieved low sudden cardiac death
recurrence rates (average 1% to 2% annually) and a high
percentage of appropriate ICD therapy ( > 98% of
successful reversion of VT with circulatory collapse or
VF).
In the context of secondary prevention of sudden
cardiac death, several trials are recently published. The
26

randomized Antiarrhythmics Versus Implantable
Defibrillators (AVID) trial30 showed that in survivors
of ventricular fibrillation or sustained ventricular
tachycardia causing significant haemodynamic
compromise, the ICD was superior to antiarrhythmic
drugs for increasing overall survival (patients who
received an ICD had a 39% reduction in total mortality
at 1 year, a 27% reduction at two years, and a 31%
reduction at three years compared to patients in the
conventional therapy group P < 0.02).
The Cardiac Arrest Study Hamburg (CASH)
trial31 aimed to test the hypothesis that ICD therapy
would significantly reduce 2-year mortality when
compared to treatment with amiodarone, propafenone,
or metoprolol in survivors of cardiac arrest. Patients
assigned to the ICD arm before July, 1990, underwent
device placement by open thoracotomy. Those assigned
after that date received transvenous systems. Patients
in the medical treatment arm received an average of
amiodarone 300mg per day, propafenone 600mg per
day, or metoprolol 100mg per day. The primary
endpoint of the study was all-cause mortality. Secondary
endpoints included recurrent cardiac arrest requiring
cardiopulmonary resuscitation and SCD. There was a
37% reduction in overall mortality among those
assigned to the ICD treatment arm (12.1% versus 19.
6%) when compared to those receiving amiodarone or
metoprolol (P = 0.047). The mortality data comparing
amiodarone and metoprolol were similar. There was a
significant decrease in SCD in patients treated with ICD
when compared to medical management (2% versus
11%, P < 0.001).
The randomised, multicentre Canadian
Implantable Defibrillator Study (CIDS)32 compared ICD
with amiodarone therapy in patients with cardiac arrest
or haemodynamically unstable ventricular tachycardia
and left ventricular ejection fraction ≤35%. After 3 years
of follow up, patients randomized to the ICD group had
a 19.6% relative risk reduction in the primary endpoint
of all-cause mortality compared to the amiodarone
group, a difference approaching statistical significance
(25% mortality in ICD group versus 30% mortality in
the amiodarone group, P = 0.072).
In summary, these multicentre, randomized
clinical trials (AVID, CASH, CIDS) have shown the
superiority of ICD over antiarrhythmic medical therapy
in secondary prevention of sudden cardiac death and
reducing total mortality in certain groups of high risk
patients.
For trials examining the outcome of ICD
implantation on primary prevention of sudden cardiac
death, the prospective, randomized, multicentre
Automatic Defibrillator Implantation Trial (MADIT)33
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showed improved survival with the ICD implantation
in post-infarction patients with low ejection fraction (EF
¢G 0.35) and inducible non-suppressible ventricular
tachycardias (54% reduction in all-cause mortality in
the ICD group relative to conventional treatment P = 0.
009). The cardiac mortality was also significantly higher
in the conventional treatment group than the ICD group
(27% vs 12%). In view of this result, this group of
patients have been included in the AHA/ACC
indications for ICD implantation (Appendix 1).
The Coronary Artery Bypass Graft Surgery
CABG-Patch trial 34 enrolled patients with coronary
artery disease scheduled for elective CABG who also
had a LVEF less than 30% and an abnormal signalaveraged electrocardiogram (SAECG). Nine hundred
patients were randomized to receive either an ICD at
the time of CABG or usual care. There was no
significant difference in the primary endpoint of total
mortality at 30 days and a mean of 32 months. Therefore,
ICD implantation is not recommended in this group of
patients.
With the evidences available so far, the American
College of Cardiology and the American Heart
Association had published the indications for ICD
implantation in 1998 as listed in Appendix 135.
The interaction between the ICD and
antiarrhythmic agents is important. Beneficial
interactions are slowing of ventricular tachycardia
which yields improved haemodynamic tolerance,
improved ATP and low energy cardioversion success
(less battery drain from the ICD), limiting the number
of recurrence of arrhythmia which minimizes patient
discomfort and prolongs ICD battery life, preventing
or slowing supraventricular tachycardias which reduce
the number of false shocks from the ICD. The
disadvantages of combining pharmacological therapy
with the ICD are the cost and side effects of both
therapies, slowing of the ventricular tachycardia which
may result in failure to detect the arrhythmia, increased
defibrillation and pacing thresholds, worsened
haemodynamic intolerance to ventricular tachycardia.
As a result, repeated electrophysiological testing and a
meticulous follow up programme is necessary in a
patient implanted with an ICD.
An ICD is easily justifiable in those high risk
patients but unfortunately most sudden cardiac deaths
occur in a large population of patients with a rather low
risk for sudden death. The decision to implant an ICD
has major economic, social and political implications.
The cost of an ICD device and implantation is currently
expensive. The price of an ICD is around HK$150,000250,000 excluding other associated costs such as
hospitalization, operation, follow up and replacement.
J HK Coll Cardiol, Vol 7

A cost-effectiveness analysis of the MADIT trial
(MADIT/CES) found the ICD to have a costeffectiveness ratio of US$22,000-31,000 per life-year
gained comparable to the widely accepted non-cardiac
therapies such as renal dialysis (US$30,000 to 50,000
per year of life saved) 36,37 . However, the costeffectiveness ratio and direct costs are expected to come
down as the technology is improved and mass
production is achieved.
In the future, it is expected that there will be an
increasing trend for the implantation of ICDs and newer
models equipped with better detection and therapy
algorithms, haemodynamic sensors will be available.

4. Identification of Patients at Risk
Risk stratification for arrhythmogenic events and
sudden death in patients with organic heart disease,
particularly those with coronary heart disease and a
history of MI, continues to be one of the major tasks of
cardiologists, although advanced management strategies
including thrombolysis, acute PTCA and surgery
dramatically reduced the percentage of sudden deaths
following infarction. Non-invasive testing like
echocardiography and radionuclide studies, 24 hour
Holter monitoring, signal-averaged electrocardiogram
(SAECG), heart rate variability (HRV), QT dispersion,
as well as, invasive techniques such as
electrophysiological study with programmed ventricular
stimulation (VT induction) are being used.

4.1

Non-invasive testing

4.1.1 Echocardiography and Radionuclide studies
Left ventricular ejection (LVEF) has been
identified as probably the most important predictor of
total mortality and morbidity following AMI and
mortality increase exponentially as LVEF decrease from
0.40 to 0.3026. LVEF can be measured by radionuclide
cardiography or estimated by echocardiography. These
methods seem to be equal in terms of predicting total
mortality. However, in terms of arrhythmic death
prediction, studies have shown that LVEF is not a very
sensitive marker. Therefore, a combination of LVEF
and another method (e.g. SAECG, HRV, etc.) appears
promising in identifying patients at high risk of sudden
death38.
4.1.2 Holter monitoring and Heart Rate Variability
(HRV)
Post MI or heart failure patients with frequent
non-sustained ventricular tachycardia or complex
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ventricular ectopic beats during Holter monitoring were
shown to have higher risk of sudden death in various
studies. With the publication of the results from the
MADIT study 33 (discussed under Section 3.7), the
documentation of nonsustained ventricular tachycardia
in post MI patients could be accepted as indication for
invasive studies.
Heart Rate Variability (HRV) reflects the
sympathicovagal activity at the sinoatrial node. Both
sympathovagal imbalance at the cost of parasympathetic
tone and a change in the circadian rhythm of HRV are
known to be independent risk factors for arrhythmic
events (in both the pre-thrombolytic and thrombolytic
era). HRV can be assessed from 24 hour Holter
monitoring by calculation of indices which are based
on statistical operations on RR intervals (time-domain
analysis). Compared to assessment of LVEF as a risk
marker, HRV is superior with respect to prediction of
arrhythmic events and sudden death whereas both
parameters yield comparative power for prediction of
total mortality39. Four year survival was 90% for patients
with a normal standard deviation of normal-to-normal
intervals (SDNN > 100msec), while survival was only
60% in patients with depressed HRV (SDNN < 50msec).
Another study, the ATRAMI study showed that 2-year
survival in post MI patients was > 98% in patients with
SDNN > 105msec and 90% for those with SDNN
< 70msec ( P < 0.0001)39,40.
Since the predictive power of either Holter
monitoring or HRV alone is relatively low, the
combined use with other traditional risk markers like
SAECG or LVEF will result in improved risk
stratification.
4.1.3 Signal-averaged ECG (SAECG)
SAECG detecting abnormal delays of ventricular
activation by demonstrating late potentials (low
amplitude, high frequency components in the terminal
QRS complex) is a useful tool to screen out patients
who will have higher risk of developing malignant
ventricular arrhythmias. A normal SAECG will give
more than 95% confidence that the patient (postinfarction) will not have significant ventricular
tachyarrhythmias in the future. Use of the SAECG as
one of the methods for risk stratification after infarction
seems well founded. When combined with other risk
indicators (e.g. LVEF), the efficacy could be increased41.
In patients with ARVD, SAECG can identify
those with more extensive right ventricular involvement
and of inducible VT during programmed stimulation42.
In patients with dilated cardiomyopathy, SAECG might
prove useful in predicting spontaneous VT43. In patients
with HOCM, the role of SAECG is still controversial44.
28

4.1.4 Miscellaneous
QT interval dispersion as a measure of interlead
variations of QT interval duration in the surface 12lead ECG is believed to reflect regional differences in
repolarization heterogeneity and thus, may provide an
indirect marker of arrhythmogenicity. However, the use
of QT dispersion as risk stratification in post infarct,
heart failure and HOCM patients still remains
controversial45.
Other non-invasive markers of patients at risk of
sudden death include T wave alternans and baroreflex
sensitivity (BRS) measurement. The ATRAMI study40
showed that BRS is a strong and independent risk factors
for post-infarction mortality demonstrating the
usefulness of autonomic markers.

4.2

Invasive testing - Electrophysiological
Studies (EPS) and Programmed
Ventricular Stimulation

Inducible sustained ventricular tachycardia
during EPS has been shown to confer 20-30% yearly
recurrence rate of the tachyarrhythmia in post MI
patients46-58. While the VT induction protocols differ
among different centres, commonly used protocols
include using 2 different basic drive train cycle lengths
with up to 3 extra stimuli given in a tandem fashion in
2 sites (right ventricular apex and outflow tract) or using
a basic drive train cycle length of 400ms with delivery
of up to 4 extrastimulus only once in the right ventricular
apex (as described by Lee and the author)59. In the latter
study, we compared prospectively three different
stimulation protocols to examine the influence of a short
basic drive train cycle length and repetition of
extrastimuli on induction of ventricular tachycardia in
30 consecutive patients who had documented ventricular
tachycardia or fibrillation based on underlying coronary
artery disease. Protocol A used a basic drive train cycle
length of 400ms with each extrastimulus coupling
interval delivered only once. Protocol B used the same
basic drive train cycle length, but with each
extrastimulus coupling interval repeated 3 times before
decrementing. Protocol C used 300ms as the cycle
length of basic drive trains without repetition of
extrastimuli. A total of 90 inductions were performed.
The results showed that there was no clinical benefit
for repetition of extrastimuli and a short basic cycle
length of 300ms was not superior to 400ms for induction
of ventricular tachyarrhythmias59.
VT induction is particularly useful for risk
stratification in certain group of high risk patients like
the MADIT population described earlier (Section 3.7)33.
EPS guided therapy (either drug or defibrillator) can
minimize the risk of sudden cardiac death in patients
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with coronary artery disease, post MI and NSVT60. Risk
stratification using EPS in patients with NSVT and
coronary artery disease and no history of MI has been
more controversial. In patients with a poor LVEF
(≤ 0.35), a negative VT induction study did not preclude
a substantial risk of sudden death. Some centres even
advocate routine VT induction in all post MI patients
thought to be at high risk from either a low ejection
fraction or frequent or complex spontaneous ventricular
ectopia61. However, without conclusive data, routine
stimulation of such patients cannot be recommended.
The value of programmed ventricular stimulation
in diseases other than MI remains to be clarified. In
patients with dilated cardiomyopathy, induction of
sustained monomorphic VT did not reliably predict
future arrhythmic events or sudden death62. In patients
with HOCM, data had been conflicting63.
In summary, non-invasive tests like
echocardiography, Holter, HRV, SAECG are important
methods for risk stratification in post MI patients.
Patients with normal non-invasive test results do have
good prognosis (and thus further EPS is not justified).
EPS with electrical stimulation seems to be the clinically
most valuable single method to predict arrhythmic
events. However, as an invasive procedure it is not
suitable as a screening test for a large cohort. The
stepwise approach for risk stratification using first noninvasive followed by invasive procedures seem to be
the most suitable and effective approach at the present
moment64.
For the screening of asymptomatic and apparently
healthy individuals in the general public, one must
consider whether the screening method is financially
and practically possible. As coronary artery disease
remains the most common cause of sudden cardiac
death, an effective, inexpensive and non-invasive
screening method to obtain sufficient information on
potential ischaemia is awaited. At the mean time, the
best we can do is to educate the general public to reduce
risk factors for coronary artery disease. For noncoronary
causes of sudden cardiac death, screening at school or
before starting competitive sports can help identify those
individuals with asymptomatic structural heart or
electrical diseases such as HOCM, WPW and long QT
syndromes65.

5. Conclusion
In the past 30 years, we have gained much
knowledge on the epidemiology, pathophysiology,
management, primary and secondary prevention of
sudden cardiac death. Many large clinical trials on the
J HK Coll Cardiol, Vol 7

prevention of this disease are in progress. At the same
time, recent advances in treating patients with coronary
artery diseases (e.g. aspirin, thrombolytics, beta
blockers, ACEI, PTCA, bypass surgery, etc.) have
significantly reduce the mortality. Risk stratification and
identification of patients at risk remain a challenge to
the physician and the available data from the published
clinical trials apply only to several selected groups of
patients. At the extreme, one could identify a small
group of patients with multiple high risk predictors
having a high probability of death, which only accounts
for a small fraction of the total deaths. It should be
remembered, however, that even though the actual rates
are comparatively low, most sudden deaths occurs in
the very large segment of the general population not
thought to be at high risk.
In order to have an impact on the public health,
we should aim at developing cost-effective means to
identify effective risk markers and devise broader
strategies to prevent sudden death in the general
population.
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Appendix 1. ACC/AHA Guidelines for Implantation of Antiarrhythmia Devices
Since 1980, the American College of Cardiology (ACC) and the American Heart Association (AHA) have jointly engaged in the
production of guidelines in the area of cardiovascular disease. The ACC/AHA Guidelines for Implantation of Antiarrhythmia Devices
was published in the April 7, 1998 issue of Circulation and in the April 1998 issue of the Journal of American College of Cardiology35.
Indications for ICD Therapy
Class I
1. Cardiac arrest due to VF or VT not due to a transient or reversible cause.
2. Spontaneous sustained VT.
3. Syncope of undetermined origin with clinically relevant, haemodynamically significant sustained VT or VF induced at
electrophysiological study when drug therapy is ineffective, not tolerated, or not preferred.
4. Nonsustained VT with coronary disease, prior MI, LV dysfunction, and inducible VF or sustained VT at electrophysiological
study that is not suppressible by a Class I antiarrhythmic drug.
Class IIa
None.
Class IIb
1. Cardiac arrest presumed to be due to VF when electrophysiological testing is precluded by other medical conditions.
2. Severe symptoms attributable to sustained ventricular tachyarrhythmias while awaiting cardiac transplantation.
3. Familial or inherited conditions with a high risk for life-threatening ventricular tachyarrhythmias such as long QT syndrome or
hypertrophic cardiomyopathy.
4. Nonsustained VT with coronary artery disease, prior MI, and LV dysfunction, and inducible sustained VT or VF at
electrophysiological study.
5. Recurrent syncope of undetermined aetiology in the presence of ventricular dysfunction and inducible ventricular arrhythmias at
electrophysiological study when other causes of syncope have been excluded.
Class III
1. Syncope of undetermined cause in a patient without inducible ventricular tachyarrhythmias.
2. Incessant VT or VF.
3. VF or VT resulting from arrhythmias amenable to surgical or catheter ablation; for example, atrial arrhythmias associated with
the Wolff-Parkinson-White syndrome, right ventricular outflow tract VT, idiopathic left ventricular tachycardia, or fascicular
VT.
4. Ventricular tachyarrhythmias due to a transient or reversible disorder (e.g. AMI, electrolyte imbalance, drugs, trauma).
5. Significant psychiatric illnesses that may be aggravated by device implantation or may preclude systematic follow-up.
6. Terminal illnesses with projected life expectancy 6 months.
7. Patients with coronary artery disease with LV dysfunction and prolonged QRS duration in the absence of spontaneous or inducible
sustained or nonsustained VT who are undergoing coronary bypass surgery.
8. NYHA Class IV drug-refractory congestive heart failure in patients who are not candidates for cardiac transplantation.
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